Taiwan
· Delayed Price · Currency is TWD CHO Pharma Statistics
Total Valuation
CHO Pharma has a market cap or net worth of TWD 9.14 billion. The enterprise value is 6.80 billion.
| Market Cap | 9.14B |
| Enterprise Value | 6.80B |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CHO Pharma has 214.01 million shares outstanding. The number of shares has increased by 11.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 214.01M |
| Shares Change (YoY) | +11.86% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 18.51% |
| Owned by Institutions (%) | 17.00% |
| Float | 143.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,552.58 |
| PB Ratio | 3.32 |
| P/TBV Ratio | 3.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -32.05 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.52 |
Financial Position
The company has a current ratio of 20.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.81 |
| Quick Ratio | 20.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | -367.15 |
Financial Efficiency
Return on equity (ROE) is -7.42% and return on invested capital (ROIC) is -5.42%.
| Return on Equity (ROE) | -7.42% |
| Return on Assets (ROA) | -5.22% |
| Return on Invested Capital (ROIC) | -5.42% |
| Return on Capital Employed (ROCE) | -9.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.78% in the last 52 weeks. The beta is -0.24, so CHO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | -21.78% |
| 50-Day Moving Average | 53.46 |
| 200-Day Moving Average | 56.46 |
| Relative Strength Index (RSI) | 38.79 |
| Average Volume (20 Days) | 376,213 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHO Pharma had revenue of TWD 3.58 million and -212.23 million in losses. Loss per share was -0.99.
| Revenue | 3.58M |
| Gross Profit | 1.71M |
| Operating Income | -249.29M |
| Pretax Income | -212.23M |
| Net Income | -212.23M |
| EBITDA | -237.71M |
| EBIT | -249.29M |
| Loss Per Share | -0.99 |
Balance Sheet
The company has 2.37 billion in cash and 28.90 million in debt, giving a net cash position of 2.34 billion or 10.92 per share.
| Cash & Cash Equivalents | 2.37B |
| Total Debt | 28.90M |
| Net Cash | 2.34B |
| Net Cash Per Share | 10.92 |
| Equity (Book Value) | 2.75B |
| Book Value Per Share | 12.84 |
| Working Capital | 2.30B |
Cash Flow
In the last 12 months, operating cash flow was -217.38 million and capital expenditures -5.49 million, giving a free cash flow of -222.87 million.
| Operating Cash Flow | -217.38M |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -222.87M |
| FCF Per Share | -1.04 |
Margins
| Gross Margin | 47.77% |
| Operating Margin | -6,963.49% |
| Pretax Margin | -5,928.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHO Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.86% |
| Shareholder Yield | -11.86% |
| Earnings Yield | -2.32% |
| FCF Yield | -2.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHO Pharma has an Altman Z-Score of 57.65.
| Altman Z-Score | 57.65 |
| Piotroski F-Score | n/a |